The common digital strategy playbook is: unify the data, layer on AI, and drive enterprise-level insight.
The strategy sounds compelling in its simplicity. And for some industries and some use cases, it can work.
But in regulated life sciences manufacturing, there is a constraint that fundamentally shapes how intelligence must be applied:
Manufacturing insight must be grounded in validated execution.
Life sciences manufacturers are investing heavily in digital transformation and AI initiatives. Industrial data fabrics are often positioned as the foundation—promising unified access to operational data across sites, systems, and functions.
This two-part blog series is written for life sciences manufacturing, IT, and quality leaders evaluating how AI and analytics architectures should be deployed, and context preserved, in regulated production environments.
In regulated life sciences manufacturing, analytics that sit above operations lack the inherent, validated context required to support quality, compliance, and release decisions.
The reality of regulated manufacturing systems: execution is the system of record
In regulated manufacturing environments, the system of record is not a dashboard or analytics platform. It is the batch record. The executed workflow. The material genealogy. The deviation review. The release decision.
These are not just operational artifacts. They are legally binding records that determine whether a therapy can be released to patients. Any insight that influences quality, yield, or release decisions must ultimately trace back to validated execution systems in life sciences manufacturing—such as those built on the DeltaV™ Automation Platform for Life Sciences.
Industrial data fabrics play an important role by unifying OT and IT data and enabling enterprise level visibility and access. However, many data fabric architectures are intentionally designed to sit above operations. They observe, analyze, and recommend, often without being bound to the same rigorous governance and validation requirements as execution systems.
In life sciences, separation matters.
Data integrity and the system of record
Data integrity is a foundational requirement in regulated environments. Decisions affecting product quality must always be grounded in the same data that serves as the system of record for GxP reporting.
Modern analytics architectures often stream operational data from control systems into external platforms for visualization and AI modeling. While efficient, this approach can introduce subtle risk when the streamed dataset diverges even slightly from the validated execution record.
The result is often two parallel views of reality:
- System of record data used for batch records and compliance
- Analytics datasets used for dashboards and models
As explored in Emerson Automation Experts’ discussion on why context is critical for life sciences data, analytics that lose execution context fail to support regulated decision making.
For life sciences manufacturers, intelligence that operates on disconnected copies of operational data cannot reliably guide actions that affect product quality or release.
Why analytics “above” execution fails in regulated life sciences
Analytics platforms that sit outside validated execution systems are often effective at identifying patterns in single variables or simplistic metrics:
- Temperature trends
- Yield drift
- Equipment performance metrics
What they often lack is regulated context:
- Which batch phase was active
- Whether the step was under deviation
- If QA approval had been granted
- Whether parameter changes were within validated limits
- How material genealogy affects risk
Without this context, analytics may surface signals—but they cannot support regulated decisions such as batch release, deviation resolution, or real-time release strategies.
In life sciences manufacturing, transformation occurs when insight is directly connected to how medicine is made, not just how data is analyzed.
Understanding dynamic process behavior in batch manufacturing
Manufacturing processes are inherently dynamic. Batches progress through phases, unit procedures, and operations where the relevant analysis window constantly shifts.
For example, analyzing a reactor temperature ramp requires aligning data to the precise moment a batch enters that phase – not a fixed timestamp. Multiply this challenge across multiple products, hundreds of units, dozens of phases, and/or thousands of signals, and the dynamic nature of the analysis increases dramatically. Moreover, the variable is itself time-dependent within the dynamic window.
Traditional enterprise analytics tools struggle in this environment because they are not designed to be phase aware or process dynamics aware. Without this alignment, comparing batches, identifying process signatures, or building reliable models becomes difficult and error prone.
Life sciences manufacturers do not lack data.
They lack intelligence that understands regulated execution.
The challenge is not to apply more analytics or unify more data using the “common” approach.
The challenge for life sciences is ensuring that insight remains traceable and inseparable from validated workflows, governed approvals, and the systems of record that determine product release.
So, the next question naturally becomes:
What does intelligence look like when it is embedded inside regulated execution—rather than layered above it?
In Part 2, we explore how execution aware architectures enable compliant, scalable AI by embedding intelligence directly into the systems that govern how medicine is made.
